Conatus Pharmaceuticals Secures $7,500,000 Series B Financing

  • Feed Type
  • Date
    4/13/2011
  • Company Name
    Conatus Pharmaceuticals
  • Mailing Address
    4365 Executive Drive San Diego, CA 92121
  • Company Description
    The Conatus team pioneered the science of apoptosis and the clinical development of pan caspase inhibitors, validating this first-in-class technology. Conatus has well established relationships with key opinion leaders in the fields of hepatology, infectious disease and inflammation.
  • Website
    http://www.conatuspharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $7,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010.
  • M&A Terms
  • Venture Investor
    MPM Capital